Yahoo Finance

Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure

Ghent, Belgium – 23 January 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...
Yahoo Finance

Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first ...

Ghent, Belgium – 15 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...
Mena FN

Sequana Medical Announces First Patient Enrolled In Mojave, A Us Randomized Controlled Phase 1/2A Study Of Dsr® 2.0 For Treatment Of Congestive Heart Failure

Ghent, Belgium – 10 Ju ly 202 3 – Sequana Medical NV (Euronext Brussels: SEQUA ) (the " Company " or " Sequana Medica l "), a pioneer in the treatment of fluid overload in liver disease, heart failure ...